SG11201405359YA - Topical gels containing alpha connexin c-terminal (act) peptides - Google Patents

Topical gels containing alpha connexin c-terminal (act) peptides

Info

Publication number
SG11201405359YA
SG11201405359YA SG11201405359YA SG11201405359YA SG11201405359YA SG 11201405359Y A SG11201405359Y A SG 11201405359YA SG 11201405359Y A SG11201405359Y A SG 11201405359YA SG 11201405359Y A SG11201405359Y A SG 11201405359YA SG 11201405359Y A SG11201405359Y A SG 11201405359YA
Authority
SG
Singapore
Prior art keywords
peptides
act
terminal
gels containing
containing alpha
Prior art date
Application number
SG11201405359YA
Other languages
English (en)
Inventor
Gautam Ghatnekar
Original Assignee
Firststring Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Firststring Res Inc filed Critical Firststring Res Inc
Publication of SG11201405359YA publication Critical patent/SG11201405359YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
SG11201405359YA 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides SG11201405359YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605528P 2012-03-01 2012-03-01
PCT/US2013/028727 WO2013131040A1 (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Publications (1)

Publication Number Publication Date
SG11201405359YA true SG11201405359YA (en) 2014-09-26

Family

ID=49083360

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405359YA SG11201405359YA (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Country Status (17)

Country Link
US (5) US8846605B2 (cg-RX-API-DMAC7.html)
EP (1) EP2819682B1 (cg-RX-API-DMAC7.html)
JP (1) JP6185937B2 (cg-RX-API-DMAC7.html)
KR (1) KR102038948B1 (cg-RX-API-DMAC7.html)
CN (1) CN104271142B (cg-RX-API-DMAC7.html)
AU (1) AU2013225716B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021653B1 (cg-RX-API-DMAC7.html)
CA (1) CA2866115C (cg-RX-API-DMAC7.html)
DK (1) DK2819682T3 (cg-RX-API-DMAC7.html)
IL (1) IL234380B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN07420A (cg-RX-API-DMAC7.html)
MX (1) MX351881B (cg-RX-API-DMAC7.html)
NZ (1) NZ629769A (cg-RX-API-DMAC7.html)
RU (1) RU2657535C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201405359YA (cg-RX-API-DMAC7.html)
WO (1) WO2013131040A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406373B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
US11246821B2 (en) * 2016-08-30 2022-02-15 Rohm And Haas Company Personal care composition
BR112019017087A2 (pt) * 2017-02-16 2020-04-14 Firststring Res Inc composição e métodos para prevenir a lesão por radiação e promover a regeneração do tecido.
JP6901801B2 (ja) * 2017-06-14 2021-07-14 バイオソリューション カンパニー・リミテッドBio Solution Co Ltd 物質pを含むしわの改善または抗炎症化粧料組成物
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020056144A1 (en) * 2018-09-12 2020-03-19 Firststring Research, Inc. Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов
US11751056B2 (en) * 2020-08-31 2023-09-05 Oracle International Corporation Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
JP2024516834A (ja) * 2021-04-30 2024-04-17 イノベント バイオロジクス(スーチョウ)カンパニー,リミティド Oxm3保存剤、oxm3製剤および調製方法
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603444A1 (de) 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2080538A1 (en) 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5401504B1 (en) * 1993-12-28 1998-04-21 Univ Mississippi Medical Cente Use of tumeric in wound healing
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US7098190B1 (en) 1999-01-27 2006-08-29 Coda Therapeutics Ltd. Formulations comprising antisense nucleotides to connexins
WO2000069896A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
EP1387692A4 (en) 2000-11-11 2004-07-21 Arbor Vita Corp MOLECULAR INTERACTIONS IN HEMATOPOETIC CELLS
US7364750B2 (en) 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにedhf
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
WO2004073616A2 (en) 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
CN1922320B (zh) 2003-12-03 2013-04-24 科达治疗(新西兰)有限公司 靶向连接蛋白的反义化合物及其使用方法
EP1827480B1 (en) * 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
CN101151043B (zh) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
KR20080018268A (ko) * 2005-06-17 2008-02-27 리지너크스 바이오 파마소티컬스, 인코포레이티드 조직 악화, 부상 또는 손상을 치료하거나 또는 예방하기위한 엘케이케이티이티 및/또는 엘케이케이티엔티 조성물들및 그 방법
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
WO2007044487A1 (en) * 2005-10-11 2007-04-19 Dfb Pharmaceuticals, Inc. Surfactant-free dispersions, compositions, and use in topical formulations
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
PL2101791T3 (pl) 2006-12-11 2015-04-30 Coda Therapeutics Inc Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
US20110130345A1 (en) 2007-06-21 2011-06-02 Baerbel Rohrer Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
CA2592285C (en) 2007-06-28 2019-10-01 Musc Foundation For Research Development Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
AU2008335717A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CN102920996A (zh) 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
EP2252690A2 (en) 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343840A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
JP2011507860A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス, インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
AU2008343754A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
EP2237796A2 (en) 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
EP2237795A2 (en) 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
US20110243964A1 (en) 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
WO2009097077A2 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
WO2009148613A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).

Also Published As

Publication number Publication date
CA2866115C (en) 2020-03-24
KR102038948B1 (ko) 2019-11-26
CN104271142B (zh) 2017-07-04
MX2014010501A (es) 2015-03-09
JP2015513549A (ja) 2015-05-14
EP2819682A4 (en) 2016-01-06
AU2013225716A1 (en) 2014-09-18
KR20140132388A (ko) 2014-11-17
US20210128682A1 (en) 2021-05-06
EP2819682B1 (en) 2017-05-03
AU2013225716B2 (en) 2017-10-12
US9161984B2 (en) 2015-10-20
ZA201406373B (en) 2015-12-23
BR112014021653B1 (pt) 2023-03-28
CA2866115A1 (en) 2013-09-06
BR112014021653A2 (pt) 2022-05-10
IL234380B (en) 2020-10-29
HK1205451A1 (en) 2015-12-18
US20150018284A1 (en) 2015-01-15
WO2013131040A1 (en) 2013-09-06
DK2819682T3 (en) 2017-08-21
JP6185937B2 (ja) 2017-08-23
US11524049B2 (en) 2022-12-13
RU2014139668A (ru) 2016-04-20
MX351881B (es) 2017-11-01
RU2657535C2 (ru) 2018-06-14
EP2819682A1 (en) 2015-01-07
US12128086B2 (en) 2024-10-29
IN2014DN07420A (cg-RX-API-DMAC7.html) 2015-04-24
US20230263857A1 (en) 2023-08-24
CN104271142A (zh) 2015-01-07
US10632173B2 (en) 2020-04-28
US20130267471A1 (en) 2013-10-10
NZ629769A (en) 2016-09-30
US8846605B2 (en) 2014-09-30
US20160058834A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
IL234380B (en) Gels for local treatment containing peptides of the c-terminus of alpha connexin
DK3415525T3 (da) Amfipatisk peptid
HRP20190454T1 (hr) Rekombinantni faktor viii proteini
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
IL239519A0 (en) Peptides as oxytocin agonists
SG11201500111VA (en) Peptides and uses thereof
SG11201405578TA (en) Pharmaceutical composition containing peptide
PT2938353T (pt) Péptidos anti-inflamatórios
IL236690B (en) Ube2t peptides and vaccines containing the same
ZA201503127B (en) Peptides
GB201501101D0 (en) Isotopic labelling of proteins
GB201200555D0 (en) Peptide
SG10201507721SA (en) CHO-GMT Recombinant Protein Expression
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
EP2891663B8 (en) Psf1-derived peptide
IL235840A0 (en) Alternaria peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
GB201221414D0 (en) Trans-locating peptide
GB201200623D0 (en) Peptide
GB201200624D0 (en) Peptide
GB201223395D0 (en) Self-assembling peptides